Progress and promise of antisense oligonucleotide therapeutics for central nervous system diseases-Reference-Cited by-同舟云学术

Progress and promise of antisense oligonucleotide therapeutics for central nervous system diseases

Published:2017-07 Issue: Volume:120 Page:56-62
ISSN:0028-3908
Container-title:Neuropharmacology
language:en
Short-container-title:Neuropharmacology

Author:

Bishop Kathie M.

Publisher

Elsevier BV

Subject

Cellular and Molecular Neuroscience,Pharmacology

Reference54 articles.

1. Antisense Pharma press release: February 26, 2013. http://www.b3cnewswire.com/20130226844/antisense-pharma-announces-revised-development-path-for-trabedersen.html.

2. Spinal needle design and size affect the incidence of postdural puncture headache in children;Apiliogullari;Paediatr. Anaesth.,2010

3. Efficiency of antisense oligonucleotide drug discovery;Bennett;Antisense Nucleic Acid. Drug Dev.,2002

4. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform;Bennett;Annu. Rev. Pharmacol. Toxicol.,2010

5. ISIS-SMNRx for the Treatment of Spinal Muscular Atrophy;Bishop,2014

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulation of human microglial gene expression and function via RNAase-H active antisense oligonucleotides in vivo in Alzheimer’s disease;Molecular Neurodegeneration;2024-04-24

2. Glymphatic dysfunction coincides with lower GABA levels and sleep disturbances in succinic semialdehyde dehydrogenase deficiency;Journal of Sleep Research;2023-12-26

3. In vivo distribution of cerebrospinal fluid tracer in human upper spinal cord and brain stem;JCI Insight;2023-12-08

4. Role of Cav2.3 (R-type) Calcium Channel in Pain and Analgesia: A Scoping Review;Current Neuropharmacology;2023-08-11

5. Antisense oligonucleotide therapy for KCNT1 encephalopathy;JCI Insight;2022-12-08